Rapid switch from intravenous epoprostenol to intravenous Remodulin(Rm) (Treprostinil sodium) in patients with stable pulmonary arterial hypertension: safety, efficacy and treatment satisfaction.
Phase of Trial: Phase IV
Latest Information Update: 04 Jan 2013
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 31 Aug 2018 Biomarkers information updated
- 24 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2009 Actual patient number (10) added as reported by ClinicalTrials.gov.